Carisma Therapeutics Inc. (NASDAQ:CARM) Given Consensus Rating of “Hold” by Analysts

Shares of Carisma Therapeutics Inc. (NASDAQ:CARM) have received a consensus rating of “Hold” from the seven analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $1.9250.

CARM has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Carisma Therapeutics in a research note on Wednesday, October 8th. D. Boral Capital reiterated a “buy” rating and set a $1.00 price target on shares of Carisma Therapeutics in a research note on Friday, August 8th. Finally, Evercore ISI upgraded Carisma Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 15th.

Insider Activity

In other news, insider Michael Klichinsky sold 119,347 shares of the company’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $0.26, for a total transaction of $31,030.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 541,329 shares of company stock worth $138,176. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Carisma Therapeutics

An institutional investor recently bought a new position in Carisma Therapeutics stock. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Carisma Therapeutics Inc. (NASDAQ:CARM) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 200,000 shares of the company’s stock, valued at approximately $62,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.48% of Carisma Therapeutics as of its most recent SEC filing. Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Price Performance

Shares of NASDAQ CARM opened at $0.06 on Friday. The business’s 50-day moving average price is $0.22 and its two-hundred day moving average price is $0.28. Carisma Therapeutics has a one year low of $0.03 and a one year high of $1.27. The company has a market capitalization of $2.36 million, a P/E ratio of -0.07 and a beta of 2.06.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.